| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| May 30, 2025 | The AI Revolution in Oncology: Lunit's Groundbreaking Advances at ASCO 2025 | The landscape of cancer treatment is shifting. Artificial intelligence (AI) is no longer a futuristic concept; it’s a present-day reality. At the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, Lunit showcased how AI is re... |
| May 26, 2025 | Lunit Highlights AI's Role in Advancing Precision Oncology at ASCO 2025 with 12 Studies | SEOUL, South Korea, May 26, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI for cancer diagnostics and therapeutics, today announced that 12 studies featuring its AI-powered digital pathology solution will be presented ... |
| May 5, 2025 | SignPath Pharma Announces ASCO 2025 Abstract Featuring LipoCurc for Glioblastoma | SignPath Pharma, developer of LipoCurc™, a liposomal curcumin formulation in clinical development for glioblastoma
Phase I/II study of LipoCurc™ in glioblastoma accepted for poster presentation at ASCO 2025, in collaboration with Johns Hopk... |
| Apr 25, 2025 | New Data at AACR Annual Meeting Highlights Use of DecisionDx®-Melanoma to Identify Early-Stage Melanoma Patients at High Risk of Distant Metastasis | FRIENDSWOOD, Texas, April 25, 2025 (GLOBE NEWSWIRE) -- Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, will share new research intended to improve the care of patients wi... |
| Apr 23, 2025 | Perspective Therapeutics Announces Acceptance of VMT-α-NET and VMT01 Data for Presentation at the 2025 ASCO Annual Meeting | SEATTLE, April 23, 2025 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company pioneering advanced treatments for cancers throughout the body, today announced... |
| Feb 17, 2025 | Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025 | Bladder Cancer: Upstaging and risk mitigation with Blue Light Cystoscopy in NMIBC featured at ASCO GU 2025
Mon, Feb 17, 2025 07:30 CET Report this content
Press Release – Oslo, Norway, February 17, 2025: Photocure ASA (OSE: PHO), The Bladde... |
| Nov 28, 2024 | The Double-Edged Sword of Innovation in Medicine | In the world of medicine, innovation is a double-edged sword. On one side, it brings hope and healing. On the other, it can lead to unforeseen consequences. Recent developments in the pharmaceutical landscape highlight this dichotomy vividl... |
| Nov 27, 2024 | Kelun-Biotech's TROP2 ADC Sacituzumab tirumotecan (sac-TMT) Approved For Marketing By NMPA Of China For 2L+ Advanced or Metastatic TNBC | CHENGDU, China, Nov. 27, 2024 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that the Company received marketing authorization in China from National Medical Products Administration (NM... |
| Aug 1, 2024 | Oncolytics Biotech® Reports Second Quarter 2024 Financial Results and Operational Highlights | Received productive feedback from Type C meeting with the FDA for the planned registration-enabling trial for pelareorep in HR+/HER2- metastatic breast cancer
On track to report overall survival results from randomized BRACELET-1 breast can... |
| Jun 5, 2024 | Oricell Presented Long-term Follow-up Data of OriCAR-017 in RRMM at 2024 ASCO Annual Meeting, Highlighting the Sustained Efficacy of GPRC5D CAR-T Therapy | SHANGHAI and ROSELAND, N.J., June 5, 2024 /PRNewswire/ -- Oricell Therapeutics, a pioneering clinical-stage biopharmaceutical company, has presented the two-year long-term follow-up results of OriCAR-017, an open-label Phase I study evaluat... |
| Jun 5, 2024 | RemeGen Showcases Research Results at American Society of Clinical Oncology (ASCO) 2024 Annual Meeting, Highlighting Its Prolific Innovation in Global Cancer Treatment | YANTAI, China, June 5, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, showcased its innovation in the field of global cancer treatmen... |
| Jun 4, 2024 | RemeGen Reports Proof-of-Concept Phase I/II Clinical Study Results for Self-Developed, Potential First-in-Class Antibody-Drug Conjugate RC88 | YANTAI, China, June 4, 2024 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, presented the results of the first-in-human, single-arm, open-l... |
| Jun 3, 2024 | NeoImmuneTech's New Data at ASCO 2024 Highlights Enhanced Benefits of Combining NT-I7 with Checkpoint Inhibitors (CPI) in Immuno-Oncology | Results from study NIT-110 with NT-I7 and CPI combination treatment show median overall survival (mOS) improvements over standard of care treatment in pancreatic cancer and MSS colorectal cancer
Correlative analysis identified potentially p... |
| Jun 1, 2024 | ASCO: New ‘Armored’ CAR produces significant responses | The “armored” huCART19-IL18 is an anti-CD19 CAR that was further modified to secrete the pro-inflammatory cytokine, interleukin 18 (IL 18).
CHICAGO – While CAR T cell therapy has revolutionized treatment for many blood cancers, including no... |
| May 31, 2024 | Adaptive Biotechnologies Announces Data Supporting the Clinical Benefits of MRD Assessment with clonoSEQ® To Be Presented at the Upcoming 2024 ASCO Annual Meeting and EHA2024 Hybrid Congress | More than 20 abstracts will be presented from clinical trials and real-world evidence using clonoSEQ for MRD assessment across multiple types of blood cancers
SEATTLE, May 31, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (N... |
| May 24, 2024 | Lunit to Showcase 7 Studies at ASCO 2024, including AI Innovations in HER2 Quantification, and Multimodal Predictive Models for Immunotherapy Response | - Lunit's ASCO 2024 presentations to highlight advances including HER2 ultra-low detection and AI-powered ICI response prediction models for NSCLC, demonstrating the impact of Lunit SCOPE suite on precision oncology
SEOUL, South Korea, May ... |
| May 24, 2024 | xCures to showcase the value of its healthcare data platform at the 2024 ASCO Annual Meeting | xCures' patient-centric platform enables outcomes monitoring and evidence generation, providing insights into the best treatments, including for rare cancers.
xCures has done what no one else has been able to do for rare diseases”
— Paul Ke... |
| May 24, 2024 | HUTCHMED Highlights Presentations at the 2024 ASCO Annual Meeting | HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., May 23, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that new and updated data from several studies of compounds discovered by... |
| Sep 19, 2023 | A popular breast cancer genomic test underestimates risks for Black women | When a woman first learns she has breast cancer, her mind immediately floods with “what now?” questions as she grapples with how this disease will impact her life.
Unfortunately, Black women also have to ask themselves, “Will my racial heri... |
| Sep 13, 2023 | Belong.Life Launches AI Clinical Trial Matching Assistant for Cancer | What You Should Know:
– Belong.Life today announced the launch of Tara, a new conversational AI SaaS solution to assist health providers and CROs with cancer clinical trial matching and recruitment.
– Available as a SaaS solution for provid... |
| Jul 10, 2023 | Résumé des anticorps conjugués présentés lors de la réunion annuelle de 2023 de l'American Society of Clinical Oncology | Les anticorps conjugués (ADC) étaient l'une des classes de médicaments les plus populaires présentées lors de la réunion annuelle de l'ASCO plus tôt ce mois-ci.
Le tableau d'analyse d'OBiS des résumés de la réunion annuelle de l'ASCO 2023 a... |
| Jun 27, 2023 | Summary of Antibody Drug Conjugates (ADCs) Presented at the American Society of Clinical Oncology 2023 Annual Meeting | Antibody Drug Conjugate (ADC) Targets
Antibody Drug Conjugates (ADCs) were one of the most popular drug classes presented at the ASCO annual meeting earlier this month.
The OBiS spreadsheet of ASCO 2023 annual meeting abstracts with drug ta... |
| Jun 23, 2023 | The ADCs of ASCO 2023 | Figure 1: Number of ADCs by target presented at the ASCO 2023 annual meeting
Antibody Drug Conjugates (ADCs) were one of the most popular drug classes presented at the ASCO annual meeting earlier this month.
The OBiS spreadsheet of ASCO 202... |
| Jun 11, 2023 | ASCO Recap: Multiple Myeloma Moves, ADC Advances & Brain Cancer Progress | Each June, physicians and scientists from the global cancer community convene in Chicago for one of the largest medical meetings of the year. The annual meeting of the American Society of Clinical Oncology drew more than 40,000 people to Mc... |
| Jun 7, 2023 | SimcereZaiming showcases latest R&D progressed on its debut at ASCO， as 6 studies regarding 3 products published at ASCO | Bijoyesh Mookerjee，M.D., CMO of Simcere Zaiming（left 4）held pleasant conversation with visitors at Zaiming’s booth
Zaiming showcased the company’s innovative R&D pipeline at ASCO Booth
Simcere Zaiming, an innovative oncology-focused bio... |
| Jun 6, 2023 | Major Breakthrough in Treating Rare Liver Cancer in Young Patients | Dr. Robert Nagourney releases 20-year cancer study
Nagourney Cancer Institute’s Drug Selection Platform Paves the Way for Personalized Treatment in Fibrolamellar Carcinoma.
This represents the first successful application of a drug response... |
| Jun 5, 2023 | ASCO 2023: RemeGen Exhibits Promising Results of Disitamab Vedotin in Bladder Cancer | YANTAI, China, June 5, 2023 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, announced the latest clinical research results on disitamab ved... |
| Jun 4, 2023 | Roswell Park Study May Provide Clues to Treating Colorectal Cancer More Effectively in Younger Patients | "This idea arose from my wanting to investigate the question of what factors at the metabolic level may be influencing the rise in young-onset colorectal cancer."
Chicago, IL (PRWEB) June 04, 2023
While the incidence of colorectal... |
| May 31, 2023 | Aspira Women’s Health Announces the Publication of Three Abstracts by the American Society of Clinical Oncology (ASCO) Supporting the Clinical Utility of OvaSuite(SM) Ovarian Cancer Risk Assessment Tests | /EIN News/ --
AUSTIN, Texas, May 31, 2023 (GLOBE NEWSWIRE) -- Aspira Women’s Health Inc. (“Aspira”) (Nasdaq: AWH), a bio-analytical based women’s health company focused on the development of gynecologic disease diagnostic tools, announced t... |
| May 29, 2023 | AMP945 Combined with FOLFIRINOX Enhances Treatment Effects in model of Pancreatic Cancer | HIGHLIGHTS
Amplia's highly selective FAK inhibitor AMP945, when used in combination with FOLFIRINOX, enhances survival in a preclinical model of pancreatic cancer
FOLFIRINOX is the most widely used treatment for pancreatic cancer patients i... |
| May 26, 2023 | xCures showcases the Power of its Real-time Clinical data platform at ASCO Annual Meeting 2023 | Real-world patient data gives valuable insights, such as collecting data on rare cancers and showing real-world side effects of treatment combinations.
Access to real-time, longitudinal, uninterrupted clinical data offers an unparalleled ca... |
| May 26, 2023 | Lunit Demonstrates Predictive Value of AI-Biomarker Platform at the 2023 ASCO Annual Meeting | - New studies reveal Lunit SCOPE's impact on predicting clinical outcomes, analyzing tumor microenvironment, and enhancing personalized cancer treatment
SEOUL, South Korea, May 26, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ), a global leader... |
| May 25, 2023 | BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO | BerGenBio Announces Abstracts Accepted for Presentation at 2023 ASCO
Thu, May 25, 2023 07:00 CET Report this content
- Oral presentation to reveal data from trial evaluating bemcentinib in relapsed mesothelioma -
- Trial-in-Progress poster ... |
| May 25, 2023 | CHOSA Oncology AB presents clinical phase 2 results of LiPlaCis and its Drug Response Predictor test at ASCO 2023 | CHOSA Oncology AB presents clinical phase 2 results of LiPlaCis and its Drug Response Predictor test at ASCO 2023
Thu, May 25, 2023 23:01 CET Report this content
CHOSA Oncology AB today publishes results from the prospective phase 2 study o... |
| May 25, 2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class |
| May 25, 2023 | Interim Results From Phase 1/2 Clinical Trial in Solid Tumor Cancers Demonstrate Aulos Bioscience’s AU-007 is Well Tolerated and Uniquely Reduces Regulatory T Cells | New data in ASCO 2023 abstract show continued trend in decreasing Tregs and eosinophils, bolstering novel mechanism of action of AU-007, Aulos’ computationally designed antibody in the IL-2 class
Initial anti-tumor activity has been observ... |
| May 11, 2023 | Kinnate Biopharma Inc. Reports First Quarter 2023 Financial Results and Recent Corporate Updates | Presented positive monotherapy dose escalation data for exarafenib, an investigational pan-RAF inhibitor, at the 2023 AACR Annual Meeting
Provided update on ongoing exarafenib monotherapy dose expansion; data-informed strategy prioritizes e... |
| May 10, 2023 | Lunit to Present 16 Abstracts at the 2023 ASCO Annual Meeting | - Lunit and collaborators demonstrate the predictive value and analytical prowess of Lunit's AI-biomarker platform in a wide range of cancer types and clinical practices
SEOUL, South Korea, May 10, 2023 /PRNewswire/ -- Lunit (KRX:328130.KQ)... |
| May 9, 2023 | Roche Forks Over $70M for Brain-Penetrating Cancer Drug Candidate | When breast cancer spreads, one of the places it’s likely to go is the brain. Roche is adding to its cancer drug pipeline by acquiring an early-stage compound with the potential to address cancer in the brain.
Roche has agreed to pay $70 mi... |
| Feb 22, 2023 | Study shows the power of eating a plant-based diet for lowering men's risk of prostate cancer | Load up your grocery cart with food supporting men's health
Dr. David Samadi reviews the latest research showing the benefits of a plant-based diet reducing risk of prostate cancer
Plant-based foods are a nutritional powerhouse for men’s he... |
| Feb 20, 2023 | Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC | Clinical data presented at ASCO GU demonstrates reduced risk of recurrence in non-muscle invasive bladder cancer with the use of BLC
Mon, Feb 20, 2023 07:30 CET Report this content
Press release – Oslo, Norway, February 20, 2023: Photocure ... |
| Jan 18, 2023 | Lunit Highlights the Effectiveness of AI in Predicting Cancer Treatment Outcomes - Findings to be Presented at ASCO GI 2023 | Lunit to present two abstracts featuring Lunit SCOPE IO, the company's AI biomarker for immune phenotyping
Lunit's presentations this year will highlight the effectiveness of Lunit SCOPE IO as a biomarker to predict treatment outcomes in li... |
| Aug 10, 2022 | Fred Hutch spinout lands $10M for precision test to guide cancer treatment, develop drugs | SEngine CEO and chief scientific officer Carla Grandori. (SEngine Photo)
Seattle startup SEngine Precision Medicine has raised $10 million to propel drug discovery and development and advance its test that tailors drugs to cancer patients.
... |
| Jun 6, 2022 | Roswell Park Expert to Present on Effectiveness of New Combination for Acute Myeloid Leukemia | In a talk at ASCO 2022, Eunice Wang, MD, will present long-term results from a phase 2 trial of crenolanib with chemotherapy for treatment of adults with newly diagnosed FLT3-mutant AML. "Our results were highly promising, with more th... |
| Jun 6, 2022 | BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022 | BERGENBIO PRESENTS CLINICAL DATA ON BEMCENTINIB IN COMBINATION WITH DOCETAXEL IN PATIENTS WITH PREVIOUSLY TREATED ADVANCED NSCLC AT ASCO ANNUAL MEETING 2022
Mon, Jun 06, 2022 18:18 CET Report this content
Bergen, Norway, 6 June 2022 – BerGe... |
| Jun 3, 2022 | Roswell Park-Led Study: Brentuximab Vedotin and Chemotherapy an Effective Treatment for Hodgkin Lymphoma | Kara Kelly, MD, led research showing that brentuximab vedotin with standard chemotherapy is safe and effective as treatment for high-risk pediatric/adolescent Hodgkin lymphoma. “This study was the first to he first to establish that brentux... |
| May 31, 2022 | QureBio Ltd. to Showcase its Q-1802 Clinical Advances at 2022 ASCO Annual Meetings | SHANGHAI, May 31, 2022 /PRNewswire/ -- QureBio Ltd., a clinical-stage biopharmaceutical company focusing on bi-specific antibodies and other engineered bio-therapeutics for the treatment of cancer, inflammation, and other serious disorders,... |
| May 27, 2022 | Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022 | Lytix Biopharma AS announces that an abstract on LTX-315 in combination with Adoptive Cell Therapy is selected for a poster presentation at ASCO 2022
Fri, May 27, 2022 08:00 CET Report this content
Oslo, Norway, May 27, 2022 – Lytix Biophar... |
| May 27, 2022 | New Studies at ASCO 2022 Validate Effectiveness of Lunit AI as Diagnostic Aid in Cancer Treatment | Lunit to showcase 7 poster presentations and 4 online publications, the company's largest publication set at ASCO to date
Findings demonstrate the practical effectiveness of Lunit's AI solutions in the pathological assessment of tumors acro... |
| May 27, 2022 | ASCO | OriCell Therapeutics Announces Oral Presentation at 2022 ASCO Annual Meeting Detailing Results from Phase I POLARIS Study of OriCAR-017 | SHANGHAI, May 27, 2022 /PRNewswire/ -- OriCell Therapeutics Co., Ltd (OriCell), a leading innovative biopharmaceutical company pioneering novel oncology cell therapies for the unmet medical needs in in hematology and oncology, today announc... |
| May 27, 2022 | I-Mab Reports Latest Phase 2 Clinical Data of its Differentiated CD73 Antibody Uliledlimab | - Uliledlimab appears safe and well-tolerated as a monotherapy and a combination therapy with toripalimab with no dose limiting toxicity
- Encouraging efficacy signals were observed in a non-small cell lung cancer (NSCLC) patient cohort
- R... |
| May 24, 2022 | Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting | BEIJING, May 24, 2022 /PRNewswire/ -- Eucure Biopharma, a wholly owned subsidiary of Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen"), today announced that it will present two posters at the 2022 ASCO Annual Meeting, ... |
| Apr 28, 2022 | Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO | Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO
Thu, Apr 28, 2022 07:00 CET Report this content
Oslo, Norway, 28 April 2022 - Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target ... |
| Apr 27, 2022 | Cancer Antibodies Announces Abstract Accepted for Presentation at American Society of Clinical Oncology Annual Meeting | Cancer Antibodies Logo
Dr. Elliot Davis to present abstract "Novel Platform for Identifying Multiple Cancer-Specific Antigens” on Sunday, June 5 from 8:00am-11:00am CT in Chicago LONGWOOD, FLORIDA, UNITED STATES, April 27, 2022 /EINPre... |
| Nov 1, 2021 | Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer | LOS ANGELES, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes,... |
| Nov 1, 2021 | Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer - Form 8-K | Aadi Bioscience Appoints Scott Giacobello as Chief Financial Officer
LOS ANGELES, November 1, 2021 - Aadi Bioscience, Inc. ("Aadi") (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for gen... |
| Oct 25, 2021 | Aadi Bioscience : Appoints Loretta Itri as Chief Medical Officer | LOS ANGELES, Oct. 25, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes,... |
| Oct 22, 2021 | Aadi Bioscience : Announces Publication of its Phase 2 Registrational (AMPECT) Trial of nab-Sirolimus in Patients with Malignant Perivascular Epithelioid Cell Tumors in the Journal of Clinical Oncology | LOS ANGELES, Oct. 22, 2021 (GLOBE NEWSWIRE) -- Aadi Bioscience, Inc. (“Aadi”) (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined cancers with alterations in mTOR pathway genes,... |
| Sep 13, 2021 | Aadi Bioscience : Appoints Emma Reeve to its Board of Directors (Form 8-K) | Aadi Bioscience Appoints Emma Reeve to its Board of Directors
LOS ANGELES, Sept. 13, 2021 - Aadi Bioscience, Inc. ('Aadi') (Nasdaq: AADI), a clinical-stage biopharmaceutical company focusing on precision therapies for genetically-defined ca... |
| Jul 26, 2021 | Aerpio Pharmaceuticals : Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO for the Treatment of Advanced Malignant PEComa (Form 8-K) | Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
• FDA grants Priority Review and sets PDUFA target action date of November 26, 2021
LOS ANGE... |
| Jun 6, 2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Announces 33-Month Follow Up Data for Lifileucel in Advanced Melanoma at ASCO 2021 Annual Meeting | Median Duration of Response (DOR) Not Reached at 33.1 Months of Median Study Follow Up in Cohort 2 in C-144-01 Study
Early Intervention with Lifileucel Following Progression on Anti-PD-1 Therapy May Maximize Benefit
ASCO Update Conference C... |
| Jun 4, 2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Announces Clinical Data for Lifileucel in Combination with Pembrolizumab in Advanced Melanoma at ASCO 2021 Annual Meeting | 86% Overall Response Rate (ORR) and 43% Complete Response Rate in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
Initial 7 Patients Show 3 Complete Responses, 3 Partial Responses and 1 Best ... |
| May 20, 2021 | IOVANCE BIOTHERAPEUTICS, INC.
Iovance Biotherapeutics Announces Clinical Data Updates for Lifileucel in Advanced Melanoma at Upcoming ASCO 2021 Annual Meeting | 86% Overall Response Rate (ORR) for Lifileucel in Combination with Pembrolizumab in Immune Checkpoint Inhibitor (ICI) Naïve Advanced Melanoma Patients in IOV-COM-202 Clinical Study
At Median of 28-Month Study Follow up, Median Duration of R... |
| May 17, 2021 | AERPIO PHARMACEUTICALS, INC.
Aerpio Pharmaceuticals : and Aadi Bioscience Enter into a Definitive Merger Agreement (Form 8-K) | Aerpio Pharmaceuticals and Aadi Bioscience Enter into a Definitive Merger Agreement
• Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience's late-stage pipeline for genetically-defined cancers with alterations in... |
| May 17, 2021 | AERPIO PHARMACEUTICALS, INC.
Aerpio Pharmaceuticals : and Aadi Bioscience Enter into a Definitive Merger Agreement | Transaction to create Nasdaq-listed company focused on advancing Aadi Bioscience’s late-stage pipeline for genetically-defined cancers with alterations in mTOR pathway genesConcurrent $155 million PIPE financing is backed by leading life sc... |
| May 30, 2020 | Early diagnosis, not cancer drug breakthroughs, is the best way to fix the global scourge of breast cancer | Covid-19 news could be nudged out of the spotlight this weekend as the American Society of Clinical Oncology’s annual scientific meeting, this year being held virtually, mobilizes 40,000 people around the world across industry, academia, an... |
| Jan 8, 2020 | At 2020 deadline, progress in Patrick Soon-Shiong’s ‘cancer moonshot’ is hard to find | In 2016, the biotech billionaire Dr. Patrick Soon-Shiong set himself a deadline: By 2020, he would transform the fight against cancer.
With the help of a coalition of big-name companies, researchers, and physicians, Soon-Shiong vowed, he wo... |
| Jun 5, 2019 | We spoke with a key Merck executive about the strategy for its top cancer drug, a $7 billion powerhouse that could soon bring in more than $20 billion | John Moore/Getty Images
A man with cancer undergoes treatment with infusions of Merck's drug Keytruda.
Advertisement
Merck's cancer drug Keytruda uses the body's natural disease-fighting immune response to combat cancer.
It has become a pow... |
| Doing what it takes to do right by patients: A biopharma company’s commitment to continued care | As we continue to grapple with the COVID-19 pandemic, many aspects of life are at a standstill. But for people living with cancer, life-threatening conditions, and chronic diseases, health care cannot be delayed. For these people, COVID-19 ... |
| Targovax ASA: Two ONCOS-102 abstracts accepted for ASCO | Oslo, Norway, 28 April 2022 – Targovax ASA (OSE: TRVX), a clinical stage immuno-oncology company developing immune activators to target hard-to-treat solid tumors, today announces that two ONCOS-102 abstracts have been accepted for poster p... |
| Targovax announces that abstract on interim phase I clinical data from the phase I/II peritoneal trial is accepted at ASCO | The abstract will be released on 13 May on https://meetings.asco.org/am/virtual-format.
For further information, please contact:
Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: *protected email*
Media and IR enquire... |
| Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting | The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and dexamethasone in the Phase 1/2 clinical study named O-12-M1. TTNT is used in Real World Evidence to assist treatment deci... |
| ASCO recap: Breast cancer breakthrough, Mirati’s moves, Arcellx ascends & more | The annual meeting of the American Society of Clinical Oncology brought an estimated 50,000 people to Chicago’s McCormick Place aiming for insights into the latest developments in cancer treatments.
The big pharmaceutical companies always m... |
| ASCO 2022 ahead: Clinical trial updates and data readouts to watch for | The annual meeting of the American Society of Clinical Oncology kicks off in Chicago this week, the largest and most closely watched of oncology conferences. It also marks a return to an in-person gathering following ASCO’s virtual meetings... |
| Personalizing cancer care where it really happens | In the popular imagination, cancer care tends to happen in prestigious, big-city hospitals. In reality, most U.S. patients get their care from private physician practices in their own communities. Commonly known as community oncology practi... |
| PMV’s ASCO data show signs of drugging ‘undruggable’ p53 protein across tumor types | The tumor-suppressing protein p53 has long been considered a valuable target—if only drug hunters could figure out how to hit it. Many research efforts aiming to leverage the capabilities of this protein have fallen short. PMV Pharmaceutica... |
| Carisma Therapeutics to Present Latest Data from Phase 1 Clinical Trial of Engineered Macrophage Therapy at 2022 ASCO Annual Meeting | PHILADELPHIA, PA – May 26, 2022 – Carisma Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced two presentations including findings of its lead candidate, ... |